[BostonCard]

So how come I see all this "Remdesivir is a Covid-19 cure" this morning?

Probably based on this?

https://www.wsj.com/articles/gilead-says...1588166509

It's a phase 3, randomized, placebo controlled trial.

I know Gilead's CMO, and he is not someone who would speak loosely, so I'm inclined to believe that the patient's did have a benefit.  However, this statement caught my eye "He said an interim analysis would be completed this week or next." so I am struggling a bit to reconcile the message coming from Gilead that it demonstrated benefit with the statement that the interim analysis hadn't been completed.

For what it is worth, the sample size of this trial (400 patients in each arm) is much higher than the one reported from the statnews article.

I am cautiously optimistic, but will await the report of the interim analysis.

BC

---

Quick add:

Here is Gilead's statement:

https://www.gilead.com/news-and-press/pr...iviral-rem

Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral Remdesivir for COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 29, 2020-- Gilead Sciences. Inc. (Nasdaq: GILD) is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational antiviral remdesivir for the treatment of COVID-19. We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing.

BC

[BostonCard]

So how come I see all this "Remdesivir is a Covid-19 cure" this morning?

Probably based on this?

https://www.wsj.com/articles/gilead-says...1588166509

It's a phase 3, randomized, placebo controlled trial.

I know Gilead's CMO, and he is not someone who would speak loosely, so I'm inclined to believe that the patient's did have a benefit.  However, this statement caught my eye "He said an interim analysis would be completed this week or next." so I am struggling a bit to reconcile the message coming from Gilead that it demonstrated benefit with the statement that the interim analysis hadn't been completed.

For what it is worth, the sample size of this trial (400 patients in each arm) is much higher than the one reported from the statnews article.

I am cautiously optimistic, but will await the report of the interim analysis.

BC

---

Quick add:

Here is Gilead's statement:

https://www.gilead.com/news-and-press/pr...iviral-rem

Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral Remdesivir for COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 29, 2020-- Gilead Sciences. Inc. (Nasdaq: GILD) is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational antiviral remdesivir for the treatment of COVID-19. We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing.

BC